Navigation Links
Medtronic Announces Positive Nine-Month Results for Endeavor,Resolute Next Generation Drug-Eluting Stent at EuroPCR

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Professor Ian Meredith, M.D., Monash Medical Centre, Melbourne, Australia, on Tuesday presented positive nine-month results from the Medtronic RESOLUTE clinical trial at the EuroPCR meeting in Barcelona, Spain, with data showing a low number of adverse cardiac events and no protocol-defined stent thrombosis. The next-generation Medtronic (NYSE:MDT) Endeavor(R) Resolute drug-eluting stent system with new BioLinx(TM) polymer is designed to address the special needs of patients who have complex medical conditions and is engineered to match the duration of drug delivery with the longer healing duration often required by these patients.

In clinical results at nine months, the Endeavor RESOLUTE trial showed no Target Lesion Revascularization (TLR), no Target Vessel Revascularization (TVR) and a Major Adverse Cardiac Event (MACE) rate of just 7.0%. Of the trial's 130 patients, 129 (99.2%) received clinical follow-up, and 95 had angiographic follow-up. In-stent late lumen loss, the study's primary endpoint, was 0.22 mm, while in-segment late loss was 0.12 mm. In-stent Angiographic Binary Restenosis (ABR) was 1.0% percent and in-segment ABR was 2.1%.

"What is most impressive about these results is that they occurred in a patient population with complex and challenging characteristics," said Dr. Meredith, the principal investigator of the trial, noting that the average lesion length in the RESOLUTE trial was 15.5 mm and nearly 82% of enrolled patients were classified as having challenging B2/C lesions. "The RESOLUTE trial enrolled a high percentage of patients with lesions that are difficult to treat, including small vessels and long lesions, and these results are extremely promising. Zotarolimus continues to be a very potent drug in preventing restenosis while the new BioLinx polymer appears to be delivering the drug as intended."

Endeavor Resolute leverage
'"/>




Page: 1 2 3

Related medicine technology :

1. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
2. Study Supports Cost-Effectiveness of Medtronics Spasticity Treatment for Children with Cerebral Palsy
3. Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stents Positive Clinical Profile
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:8/28/2015)... LONDON , August 28, 2015 ... seamlessly connects people, technologies and care protoc ... improving outcomes and the cost of healthcare delivery   ... today announced its presence at  ESC Congress 2015 , where the ... A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect people and ...
(Date:8/27/2015)... , Aug. 27, 2015 DURECT Corporation ... scheduled to present at three upcoming healthcare conferences.  ... and CEO, will present at the Rodman & Renshaw ... Eastern time. The conference is being held at the ... . A live audio webcast of the presentation ...
(Date:8/27/2015)... 2015  Eli Lilly and Company (NYSE: LLY ... on Thursday, September 17, 2015. Sue Mahony , ... and Richard Gaynor , M.D., senior vice president ... will participate in a fireside chat at 3:30 p.m., ... webcast will be available on the "Webcasts & Presentations" ...
Breaking Medicine Technology:Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4DURECT to Participate in Upcoming Healthcare Conferences 2Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
... Ranbaxy Pharmaceuticals Inc.,(RPI), a wholly owned subsidiary of ... received approval from the U.S. Food and Drug,Administration ... USP, 7.5 mg/750 mg, 10 mg/500 mg, 5 ... of Generic Drugs, U.S. Food and Drug,Administration, has ...
... AutoGenomics, a leader in,developing automated molecular testing solutions, ... submitted to the FDA for 510(k) clearance,late last ... Medical,School-Partners HealthCare Center for Genetics and Genomics (HPCGG). ... prescribed to help prevent,blood clots. With more than ...
Cached Medicine Technology:Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP 2Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity 2
(Date:8/28/2015)... , ... August 29, 2015 , ... Rio Salado ... learning and the student experience as part of the EDUCAUSE - Next Generation Learning ... . , This is the third Breakthrough Models Incubator hosted by EDUCAUSE ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United Methodists ... celebrate children helping children, a thank you to the many creative and generous ... to the United Methodist initiative to end malaria deaths. , The Columbus Zoo ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... With the ... concert returned for the second year to the Adams County Fairgrounds in Mendon, IL ... held to raise money to support music education in the underfunded school districts of ...
(Date:8/28/2015)... ... ... As reported by Medical Daily on August 22 , Cellfina, a ... for two years, the longest of any cellulite reduction system currently on the market. ... effective solution for their cellulite, according to Dr. Robert Weiss, director of the premier ...
(Date:8/28/2015)... Manistee, Michigan (PRWEB) , ... August 28, 2015 ... ... or alcohol abuse, or those who might personally be struggling with chemical dependency, ... blog post from Best Drug Rehabilitation, a results-driven holistic treatment center for addiction ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3
... Reporter , MONDAY, Nov. 22 (HealthDay News) -- Diabetes ... a new study shows. The research, conducted at ... had a much higher risk of developing diabetes, and ... depression, compared to healthy study participants. "This study ...
... Minn. -- A new Mayo Clinic study ... low-grade brain tumors (gliomas) ( http://www.mayoclinic.org/brain-tumors/ ) ... the tumor have an increased chance of ... possible, adding radiation therapy to a less ...
... helping researchers learn whether more muscle improves the cardiovascular ... ways to counteract the unhealthy effects of fat," said ... of Georgia Vascular Biology Center and co-director of MCG,s ... the risk for cardiovascular disease as well as diabetes, ...
... Reinberg HealthDay Reporter , MONDAY, Nov. 22 (HealthDay ... taken off the market, emergency rooms treat less than half ... reactions to the drugs, a new U.S. government study shows. ... for children aged 2 and under took effect in October ...
... Biochemist and protein crystallographer Dr. Oliver Daumke of the ... has won the "Bayer Early Excellence in Science Award ... prize worth EUR 10,000 for his contributions to the ... proteins next spring in Berlin. Together with him, two ...
... , MONDAY, Nov. 22 (HealthDay News) -- Infants with Down syndrome ... risk for heart and lung disorders that increase their chances of ... medical records of more than 50,000 very low birth weight (VLBW) ... They found that among this group of babies, those born with ...
Cached Medicine News:Health News:Diabetes, Depression Can Be Two-Way Street 2Health News:Diabetes, Depression Can Be Two-Way Street 3Health News:Mayo Clinic study finds aggressive surgery is best for children with brain tumors 2Health News:Fat yet muscular mouse provides clues to improving cardiovascular health 2Health News:Kids' ER Visits Down After Cold Medicine Withdrawal 2Health News:Kids' ER Visits Down After Cold Medicine Withdrawal 3Health News:Tiniest Newborns With Down Syndrome Face Other Health Risks 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: